Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the RedePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1
July 31, 2025
July 31, 2025
CAMBRIDGE, Massachusetts, July 31 -- Arbor Biotechnologies, a biotechnology company that says it discovers and develops genetic medicines, issued the following news release:
* * *
Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1
* ABO-101 was well tolerated with no serious adverse events or dose-limiting toxicities report . . .
* * *
Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1
* ABO-101 was well tolerated with no serious adverse events or dose-limiting toxicities report . . .